RU2005101623A - Вирулентные гены, белки и их применение - Google Patents
Вирулентные гены, белки и их применение Download PDFInfo
- Publication number
- RU2005101623A RU2005101623A RU2005101623/13A RU2005101623A RU2005101623A RU 2005101623 A RU2005101623 A RU 2005101623A RU 2005101623/13 A RU2005101623/13 A RU 2005101623/13A RU 2005101623 A RU2005101623 A RU 2005101623A RU 2005101623 A RU2005101623 A RU 2005101623A
- Authority
- RU
- Russia
- Prior art keywords
- peptide
- neisseria meningitidis
- seq
- prevention
- neisseria
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract 6
- 102000004169 proteins and genes Human genes 0.000 title 1
- 241000588650 Neisseria meningitidis Species 0.000 claims abstract 8
- 229960005486 vaccine Drugs 0.000 claims abstract 5
- 230000002238 attenuated effect Effects 0.000 claims abstract 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- 230000001225 therapeutic effect Effects 0.000 claims abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 241000588653 Neisseria Species 0.000 claims 3
- 230000006806 disease prevention Effects 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 239000004599 antimicrobial Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000007423 screening assay Methods 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 244000005700 microbiome Species 0.000 abstract 1
- 230000001018 virulence Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/36—Neisseria
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (13)
1. Пептид, проявляющий свойства антигена Neisseria meningitidis, кодируемый нуклеотидной последовательностью, выбранной из группы, состоящей из последовательностей:
SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, 205, 207,
или характеризующийся, по крайней мере, 60% сходством или идентичностью к указанной последовательности на пептидном или нуклеотидном уровне, или его фрагмент, сохраняющий свойства антигена, для применения при изготовлении лекарственного препарата для лечения или предупреждения состояний, ассоциированных с инфекцией, вызываемой Neisseria или грам-отрицательными бактериями.
2. Пептид по п. 1, отличающийся тем, что указанная последовательность имеет сходство или идентичность, по крайней мере, на 90%.
3. Пептид по п. 1, отличающийся тем, что указанный пептид содержит аминокислотную последовательность, выбранную из группы, состоящую из последовательностей:
SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, 206 и 208.
4. Пептид по любому из пп.1-3, где указанным состоянием является менингит.
5. Пептид, определенный в любом из пп.1-3, для применения в скринирующем анализе для идентификации антимикробного лекарственного средства.
6. Полинуклеотид, кодирующий пептид, определенный в любом из пп.1-3, для применения при изготовлении лекарственного препарата для лечения или предупреждения состояний, ассоциированных с инфекцией, вызываемой Neisseria или грам-отрицательными бактериями.
7. Полинуклеотид по п.6, где указанным состоянием является менингит.
8. Полинуклеотид, определенный в п.6, для применения в скринирующем анализе для идентификации антимикробного лекарственного средства.
9. Вакцина для лечения или предотвращения заболеваний или состояний, вызванных Neisseria meningitidis, содержащая аттенуированный мутантный штамм Neisseria meningitidis, который содержит мутацию, нарушающую экспрессию нуклеотидной последовательности, выбранной из группы, состоящей из последовательностей:
SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, 205, 207.
10. Вакцина для лечения или предотвращения заболеваний или состояний, вызванных Neisseria meningitidis, содержащая аттенуированный мутантный штамм Neisseria meningitidis, который содержит инсерционную инактивацию или делецию гена, нарушающую экспрессию нуклеотидной последовательности, выбранной из группы, состоящей из последовательностей:
SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, 205, 207.
11. Вакцина для лечения или предотвращения заболеваний или состояний, вызванных Neisseria meningitidis, содержащая аттенуированный мутантный штамм Neisseria meningitidis, который содержит мутацию, нарушающую экспрессию нуклеотидной последовательности, выбранной из группы, состоящей из последовательностей:
SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, 205, 207
и дополнительно содержит гетерологичный антиген, гетерологичный терапевтический пептид или гетерологичную нуклеиновую кислоту.
12. Вакцина для предотвращения состояний, связанных с бактериальной инфекцией, вызванной Neisseria, содержащая пептид по любому из пп.1-3.
13. Антитело, полученное с помощью пептида, определенного в любом из пп.1-3, которое связывается с пептидом, определенным в любом из пп.1-3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0011108.8A GB0011108D0 (en) | 2000-05-08 | 2000-05-08 | Virulence gene and protein and their use |
| GB0011108.8 | 2000-05-08 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002132891/13A Division RU2252224C2 (ru) | 2000-05-08 | 2001-05-08 | Пептид со свойствами антигена neisseria meningitidis, кодирующий его полинуклеотид, вакцина для лечения или предотвращения заболеваний или состояний, вызванных neisseria meningitidis, (варианты), антитело, связывающееся с указанным пептидом |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005101623A true RU2005101623A (ru) | 2006-07-10 |
Family
ID=9891203
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002132891/13A RU2252224C2 (ru) | 2000-05-08 | 2001-05-08 | Пептид со свойствами антигена neisseria meningitidis, кодирующий его полинуклеотид, вакцина для лечения или предотвращения заболеваний или состояний, вызванных neisseria meningitidis, (варианты), антитело, связывающееся с указанным пептидом |
| RU2005101623/13A RU2005101623A (ru) | 2000-05-08 | 2005-01-24 | Вирулентные гены, белки и их применение |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002132891/13A RU2252224C2 (ru) | 2000-05-08 | 2001-05-08 | Пептид со свойствами антигена neisseria meningitidis, кодирующий его полинуклеотид, вакцина для лечения или предотвращения заболеваний или состояний, вызванных neisseria meningitidis, (варианты), антитело, связывающееся с указанным пептидом |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20040087770A1 (ru) |
| EP (2) | EP1908839A3 (ru) |
| JP (1) | JP2003532404A (ru) |
| KR (3) | KR20030032948A (ru) |
| CN (2) | CN1840665A (ru) |
| AT (1) | ATE382056T1 (ru) |
| AU (1) | AU776508B2 (ru) |
| CA (1) | CA2408738A1 (ru) |
| CZ (1) | CZ20023642A3 (ru) |
| DE (1) | DE60132084T2 (ru) |
| GB (1) | GB0011108D0 (ru) |
| HU (1) | HUP0302481A2 (ru) |
| NO (1) | NO20025329L (ru) |
| NZ (3) | NZ522277A (ru) |
| RU (2) | RU2252224C2 (ru) |
| WO (1) | WO2001085772A2 (ru) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996017951A2 (en) | 1994-12-09 | 1996-06-13 | Rpms Technology Limited | Identification of genes responsible for in vivo survival of microorganisms |
| DK1108034T3 (da) | 1998-09-04 | 2008-11-10 | Emergent Product Dev Uk Ltd | Svækkede salmonella SPI2-mutanter som antigenbærere |
| EP1163343B1 (en) | 1999-03-12 | 2009-12-09 | GlaxoSmithKline Biologicals S.A. | Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies |
| GB9910812D0 (en) | 1999-05-10 | 1999-07-07 | Microscience Ltd | Vaccine composition |
| KR101239242B1 (ko) * | 2002-08-02 | 2013-03-11 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 항원 조합물을 포함하는 나이세리아 백신 조성물 |
| GB0330007D0 (en) * | 2003-12-23 | 2004-01-28 | Imp College Innovations Ltd | Vaccines |
| US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| CN102716480B (zh) | 2005-04-08 | 2023-03-21 | 惠氏有限责任公司 | 多价肺炎球菌多糖-蛋白质缀合物组合物 |
| AU2008304231A1 (en) * | 2007-09-27 | 2009-04-02 | Albany Molecular Research, Inc. | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| EP2326344A4 (en) | 2008-06-16 | 2013-08-07 | Prokarium Ltd | VACCINES WITH SALMONELLA VECTOR AGAINST CHLAMYDIA AND METHOD OF ADMINISTRATION |
| GB0816447D0 (en) * | 2008-09-08 | 2008-10-15 | Glaxosmithkline Biolog Sa | Vaccine |
| CA2792691A1 (en) * | 2010-03-11 | 2011-09-15 | Glaxosmithkline Biologicals S.A. | Immunogenic composition or vaccine against gram-negative bacterial, for example, neisserial, infection or disease |
| CN111118043B (zh) * | 2020-01-13 | 2022-07-05 | 吉林大学 | 一种苦豆子SaMET6基因克隆及其应用 |
| CN116042562B (zh) * | 2022-03-11 | 2023-10-20 | 山东恒鲁生物科技有限公司 | 重组酵母菌及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2047043A1 (en) * | 1990-07-19 | 1992-01-20 | Allen I. Oliff | Class ii protein of the outer membrane of neisseria meningitidis having immune enhancement properties |
| US5338664A (en) * | 1992-12-04 | 1994-08-16 | American Cyanamid Company | Assay for detection of bacterial iron transport inhibitors |
| US6121037A (en) * | 1994-10-18 | 2000-09-19 | Stojiljkovic; Igor | Bacterial hemoglobin receptor genes |
| WO1996017951A2 (en) * | 1994-12-09 | 1996-06-13 | Rpms Technology Limited | Identification of genes responsible for in vivo survival of microorganisms |
| FR2751000B1 (fr) * | 1996-07-12 | 1998-10-30 | Inst Nat Sante Rech Med | Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques |
| US6472518B1 (en) * | 1996-10-24 | 2002-10-29 | Centers For Disease Control And Prevention, As Represented By The Secretary, Department Of Health And Human Services | Invasion associated genes from Neisseria meningitidis serogroup B |
| GB9711964D0 (en) * | 1997-06-09 | 1997-08-06 | Medical Res Council | Live attenuated vaccines |
| DE69836333T2 (de) * | 1997-08-15 | 2007-04-19 | Rijksuniversiteit Utrecht | Neisseria lactoferrin-bindendes protein |
| CA2308606A1 (en) * | 1997-11-06 | 1999-05-20 | Chiron S.P.A. | Neisserial antigens |
| AU3968599A (en) * | 1998-04-29 | 1999-11-16 | American Cyanamid Company | Vaccines containing recombinant pilin against Neisseria Gonorrhoeae or Neisseria Meningitidis |
| GB9811260D0 (en) * | 1998-05-26 | 1998-07-22 | Smithkline Beecham Biolog | Novel compounds |
| JP2004511201A (ja) * | 1998-10-09 | 2004-04-15 | カイロン コーポレイション | ナイセリアゲノム配列およびそれらの使用方法 |
| US6610836B1 (en) * | 1999-01-29 | 2003-08-26 | Genome Therapeutics Corporation | Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics |
| DK1185691T3 (da) * | 1999-04-30 | 2009-06-22 | Novartis Vaccines & Diagnostic | Genomiske neisseriasekvenser og fremgangmåder til anvendelse deraf |
-
2000
- 2000-05-08 GB GBGB0011108.8A patent/GB0011108D0/en not_active Ceased
-
2001
- 2001-05-08 CN CNA2005101362903A patent/CN1840665A/zh active Pending
- 2001-05-08 US US10/275,026 patent/US20040087770A1/en not_active Abandoned
- 2001-05-08 CZ CZ20023642A patent/CZ20023642A3/cs unknown
- 2001-05-08 CN CN01809191A patent/CN1427892A/zh active Pending
- 2001-05-08 AT AT01925742T patent/ATE382056T1/de not_active IP Right Cessation
- 2001-05-08 RU RU2002132891/13A patent/RU2252224C2/ru not_active IP Right Cessation
- 2001-05-08 NZ NZ522277A patent/NZ522277A/en unknown
- 2001-05-08 DE DE60132084T patent/DE60132084T2/de not_active Expired - Fee Related
- 2001-05-08 WO PCT/GB2001/002003 patent/WO2001085772A2/en active IP Right Grant
- 2001-05-08 AU AU52422/01A patent/AU776508B2/en not_active Ceased
- 2001-05-08 HU HU0302481A patent/HUP0302481A2/hu unknown
- 2001-05-08 JP JP2001582371A patent/JP2003532404A/ja active Pending
- 2001-05-08 NZ NZ549068A patent/NZ549068A/en unknown
- 2001-05-08 EP EP07114502A patent/EP1908839A3/en not_active Withdrawn
- 2001-05-08 EP EP01925742A patent/EP1287024B1/en not_active Expired - Lifetime
- 2001-05-08 CA CA002408738A patent/CA2408738A1/en not_active Abandoned
- 2001-05-08 KR KR1020027014876A patent/KR20030032948A/ko not_active Application Discontinuation
- 2001-05-08 NZ NZ532297A patent/NZ532297A/en unknown
-
2002
- 2002-11-06 NO NO20025329A patent/NO20025329L/no not_active Application Discontinuation
-
2005
- 2005-01-24 RU RU2005101623/13A patent/RU2005101623A/ru not_active Application Discontinuation
-
2007
- 2007-08-17 US US11/893,649 patent/US20080241151A1/en not_active Abandoned
- 2007-08-29 KR KR1020070087191A patent/KR20070102447A/ko not_active Application Discontinuation
-
2008
- 2008-07-10 KR KR1020080067099A patent/KR20080080069A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2408738A1 (en) | 2001-11-15 |
| EP1287024B1 (en) | 2007-12-26 |
| AU776508B2 (en) | 2004-09-09 |
| NO20025329D0 (no) | 2002-11-06 |
| NZ522277A (en) | 2004-05-28 |
| KR20070102447A (ko) | 2007-10-18 |
| WO2001085772A2 (en) | 2001-11-15 |
| AU5242201A (en) | 2001-11-20 |
| DE60132084D1 (de) | 2008-02-07 |
| NZ532297A (en) | 2005-07-29 |
| HUP0302481A2 (hu) | 2003-10-28 |
| US20040087770A1 (en) | 2004-05-06 |
| KR20030032948A (ko) | 2003-04-26 |
| US20080241151A1 (en) | 2008-10-02 |
| EP1908839A3 (en) | 2008-07-16 |
| CZ20023642A3 (cs) | 2003-04-16 |
| WO2001085772A3 (en) | 2002-03-28 |
| CN1427892A (zh) | 2003-07-02 |
| RU2252224C2 (ru) | 2005-05-20 |
| EP1287024A2 (en) | 2003-03-05 |
| KR20080080069A (ko) | 2008-09-02 |
| EP1908839A2 (en) | 2008-04-09 |
| CN1840665A (zh) | 2006-10-04 |
| DE60132084T2 (de) | 2008-12-11 |
| NO20025329L (no) | 2003-01-06 |
| GB0011108D0 (en) | 2000-06-28 |
| JP2003532404A (ja) | 2003-11-05 |
| NZ549068A (en) | 2008-03-28 |
| ATE382056T1 (de) | 2008-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005101623A (ru) | Вирулентные гены, белки и их применение | |
| Rajapakse et al. | Immunization with the RgpA-Kgp proteinase-adhesin complexes of Porphyromonas gingivalis protects against periodontal bone loss in the rat periodontitis model | |
| Atherton | H. pylori virulence factors | |
| Husmann et al. | Role of putative virulence factors of Streptococcus pyogenes in mouse models of long-term throat colonization and pneumonia | |
| AU683454B2 (en) | Heterologous antigens in live cell vaccine strains | |
| RU2002132891A (ru) | Вирулентные гены, белки и их применение | |
| CA2623339A1 (en) | Virulence genes in the vgc2 cluster of salmonella | |
| Stevens et al. | Characterization of a Haemophilus ducreyi mutant deficient in expression of cytolethal distending toxin | |
| Prado et al. | Immunogenicity of iron-regulated outer membrane proteins of Pasteurella multocida A: 3 in cattle: molecular characterization of the immunodominant heme acquisition system receptor (HasR) protein | |
| Stefanelli et al. | Molecular characterization of two Bordetella bronchiseptica strains isolated from children with coughs | |
| Aarattuthodiyil et al. | An orally delivered, live‐attenuated Edwardsiella ictaluri vaccine efficiently protects channel catfish fingerlings against multiple Edwardsiella ictaluri field isolates | |
| JP2007529195A (ja) | 歯周病の診断，治療，およびモニタリングのためのＰｏｒｐｈｙｒｏｍｏｎａｓｇｉｎｇｉｖａｌｉｓ毒性ポリヌクレオチドの同定 | |
| JPH08503136A (ja) | Ｐ．ｍｕｌｔｏｃｉｄａによるパスツレラ症に対する感染防御剤 | |
| EP1240332B1 (en) | Streptococcus pyogenes virulence genes and proteins and their use | |
| CN105797152A (zh) | 一种疫苗组合物及其制备方法和应用 | |
| CN107050442B (zh) | 用于预防β-溶血链球菌(BHS)疾病的多组分免疫原性组合物 | |
| EP2189164A1 (en) | Salmonella marker vaccine | |
| JPH07502174A (ja) | 家禽病を発症させる新規バクテリアとそれから誘導されたワクチン | |
| RU2003107837A (ru) | Гены и белки и их применения | |
| EP2244730A2 (en) | Vaccines | |
| RU2313535C2 (ru) | Пептид neisseria meningitidis для терапевтического и диагностического применения | |
| CN101177684A (zh) | 羊型布鲁氏杆菌m5菌株核糖体蛋白l7/l12的基因、其编码蛋白及应用 | |
| ATE366583T1 (de) | Identifizierung von spezifischen differenziell exprimierten antigenen aus mycobacterium und medizinische verwendung der mycobakteriumproteine rv0068 und rv3407 | |
| Tahamtan et al. | Classification, capsular PCR typing and genetic diversity of Pasteurella multocida isolated from sheep and goats in Iran using Bam HI, Hind III restriction endonuclease enzymes by PCR-RFLP. | |
| AU2001282299A1 (en) | Genes and proteins, and their uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20091026 |